PriMera Scientific Engineering (ISSN: 2834-2550)

Research Article

Volume 4 Issue 5

COVID-19 Crisis: A Brunt or Blossoming on Pharmaceutical Industry an Inspection of Sun Pharma, Cipla & Divi's Labs

Bijin Philip*, Shreya Kumari and Mahek Khetpal

April 26, 2024

DOI : 10.56831/PSEN-04-124

View PDF

Abstract

The COVID-19 pandemic has emerged as a pivotal moment for the pharmaceutical industry, catalyzing profound shifts in market dynamics and operational strategies. This research paper delves into the nuanced ramifications of the pandemic on the pharmaceutical sector, with a focused examination on three prominent entities: Sun Pharma, Cipla, and Divi's Labs. Through a comprehensive analysis, this study endeavors to elucidate whether the COVID-19 crisis has posed a formidable challenge or presented opportunities for growth within these pharmaceutical companies.

The objectives of this research are threefold. Firstly, it aims to investigate the impact of the COVID-19 pandemic on the profitability of pharmaceutical companies in India. Secondly, it seeks to scrutinize the fluctuations in share prices of Sun Pharma, Cipla, and Divi's Labs before and after the onset of the pandemic. Lastly, it endeavors to discern the relationship between key financial metrics such as revenue, profit, return on investment (ROI), and the corresponding share price performance of these companies.

Employing a combination of quantitative methodologies and qualitative insights, this study offers valuable perspectives on the resilience and adaptability of the pharmaceutical industry in the face of unprecedented global challenges. By unraveling the intricate interplay between pandemic-induced disruptions and market dynamics, this research contributes to a deeper understanding of the evolving landscape of the pharmaceutical sector amidst the COVID-19 crisis.

Keywords: COVID 19 Pandemic; Pharmaceutical Industry; Return on Investment (ROI); and Share Price Fluctuations

Reference

1. Zulfikri Agung, Tera Lesmana and Gustian Djuanda. "Impact of Covid-19 Pandemic on Financial Performance in Sub-Sector Pharmaceutical Companies Listed on the IDX". Nusantara Science and Technology Proceedings (2021): 138-144.
2. Phuong Lai Cao Mai. "How Covid-19 affects the share price of Vietnam's pharmaceutical industry: event study method". Entrepreneurship and sustainability issues 8.4 (2021): 250.
3. Pushpa A., et al. “Impact of COVID-19 on Leading Pharmaceutical Companies Stock Prices Listed in BSE, India”. Empirical Economics Letters 20 (2021).
4. Bhavyasri, Maddi Yasaswini Venkata Sai and Lalita Mohan Mohapatra. "4 Financial performance analysis of selected Indian pharmaceutical companies during COVID-19 outbreak". Building Resilient Organizations: Predicaments & Prospects (2022): 61.
5. Ichsani Sakina., et al. "Comparative study of the financial performance on pharmaceutical and healthcare companies before and during the COVID-19 pandemic". JurnalAd’ministrare 9.1 (2022): 245-254.
6. Wang Chunlei., et al. "Global financial crisis, smart lockdown strategies, and the COVID-19 spillover impacts: A global perspective implication from Southeast Asia". Frontiers in Psychiatry 12 (2021): 643783.
7. Droj L, Karanovic G and Tara IG. “The Impact of the Covid-19 Pandemics Over the Financial Performance at The Level of the Main Pharmaceutical Operating in Central and Eastern Europe”. The Annals of the University of Oradea.Economic Sciences 30.2nd (2021).
8. Ariyanto Dodik and I Jhuniantara. "Fraudulent financial statements in pharmaceutical companies: Fraud pentagon theory perspective". J. Legal Ethical & Regul 24 (2021).